Tuesday, March 19, 2013

• KKR, Hellman & Friedman to explore joint Life Technologies bid, Reuters reportstheflyonthewall.com (Tue, Mar 19)

Thursday, March 14, 2013

• FDA wants to relax criteria for Alzheimer's drug approval, NY Times saystheflyonthewall.com (Thu, Mar 14)

Tuesday, March 12, 2013

• FDA Approves Roche's New HCV TestZacks (Tue, Mar 12)
• PDLI Guides Q1 Royalty RevenueZacks (Tue, Mar 12)

Monday, March 11, 2013

• J&J Faces Potentially Disrupting Competition In Its Lucrative Glucose Monitoring Business From Tiny Diagnostics Outfitat Forbes (Mon, Mar 11)

Friday, March 8, 2013

• Tucson Symposium attracts over 450 global scientists focused on personalized healthcarePR Newswire (Fri, Mar 8)

Thursday, March 7, 2013

• Nektar Loss Widens, Gives GuidanceZacks (Thu, Mar 7)
• EU Approves Roche's PerjetaZacks (Thu, Mar 7)

Wednesday, March 6, 2013

• PDLI Beats on Higher RevenuesZacks (Wed, Mar 6)
• Legendary Drug Industry Executives Warn U.S. Science Cuts Endanger The Futureat Forbes (Wed, Mar 6)

Tuesday, March 5, 2013

• Is Apple/Genentech's Art Levinson Poised to Assume Chairman Role at Roche?at Forbes (Tue, Mar 5)
• Vertex flu treatment may become large franchise, says William Blairtheflyonthewall.com (Tue, Mar 5)
• Vertex flu treatment may become large franchise, says William Blairat theflyonthewall.com (Tue, Mar 5)

Friday, March 1, 2013

• Roche Teams Up with BiocareZacks (Fri, Mar 1)
• Preclinical Biotech Structured Deals: Reflections on 2013's Solid Startat Forbes (Fri, Mar 1)
• Testis Compositum: Pistorius' Medicine Not Medicineat Forbes (Fri, Mar 1)

Wednesday, February 27, 2013

• Pipeline Progresses at RocheZacks (Wed, Feb 27)

Tuesday, February 26, 2013

• Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate lesionsPR Newswire (Tue, Feb 26)

Monday, February 25, 2013

• FDA Approves Roche's KadcylaZacks (Mon, Feb 25)
• Amgen climbs, Affymax plummets following drug recalltheflyonthewall.com (Mon, Feb 25)

Sunday, February 24, 2013

• Genentech: Omalizumab met its primary endpoint in Phase III trial, ASTERIA llltheflyonthewall.com (Sun, Feb 24)
• Phase III Results Showed omalizumab Significantly Reduced Disease Severity in Patients with a Chronic Form of Hives who Failed Standard TherapyBusiness Wire (Sun, Feb 24)

Friday, February 22, 2013

• Roche Breast Cancer Drug To Succeed Herceptinat Investor's Business Daily (Fri, Feb 22)
• Roche, ImmunoGen Breast Cancer Drug Wins Approvalat Investor's Business Daily (Fri, Feb 22)
• Roche confirms FDA approval for Kadcylaat theflyonthewall.com (Fri, Feb 22)

Add RHHBY News to My Yahoo!